probucol has been researched along with Arteriosclerosis in 157 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation." | 7.69 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995) |
| "To explain the strong effect of probucol on xanthomas, the drug's effect on lipid storage in macrophages in the presence of denatured low-density lipoprotein (LDL) was studied." | 7.67 | Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. ( Hara, H; Takaichi, S; Tomikawa, M; Wakasugi, J; Yamamoto, A, 1988) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 6.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| "Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos." | 5.29 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994) |
| "The family members had episodes of cerebral infarction and apparently had atherosclerosis of the internal carotid artery, but no coronary heart disease due to their almost normal level of cholesterol." | 5.28 | A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. ( Fujita, H; Ihara, Y; Kajinami, K; Kamisaka, K; Kibata, M; Mabuchi, H; Namba, R; Nobukuni, K; Ohshima, K; Shirabe, T, 1991) |
| " To clarify the mechanisms underlying vascular dysfunction and oxidative stress in hypercholesterolemia, we compared the effects of antioxidant probucol with those of pravastatin on aortic stiffness, phenotypic modulation, oxidative stress, and NAD(P)H oxidase essential subunit p22(phox) expression in aortic medial SM cells of cholesterol-fed rabbits by using color image analysis of immunostained sections." | 3.71 | Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. ( Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S, 2002) |
| "In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation." | 3.69 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995) |
| "Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics." | 3.69 | Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. ( Baldassarre, D; Brusoni, B; Franceschini, G; Peruzzotti, G; Sirtori, CR, 1997) |
| "To explain the strong effect of probucol on xanthomas, the drug's effect on lipid storage in macrophages in the presence of denatured low-density lipoprotein (LDL) was studied." | 3.67 | Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. ( Hara, H; Takaichi, S; Tomikawa, M; Wakasugi, J; Yamamoto, A, 1988) |
| "02 for the dose-response relationship; P< or =0." | 2.71 | Effects of AGI-1067 and probucol after percutaneous coronary interventions. ( Bourassa, MG; Glass, M; Grégoire, J; Guertin, MC; L'Allier, PL; Lambert, J; Laramée, L; Lespérance, J; Reeves, F; Schwartz, L; Tardif, JC; Title, L, 2003) |
| "Probucol was not found to effect progression regression of femoral atherosclerosis significantly as assessed by quantitative arteriography." | 2.68 | The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. ( Elinder, LS; Holme, I; Johansson, J; Mölgaard, J; Nilsson, J; Nilsson, S; Olsson, AG; Regnström, J; Walldius, G, 1996) |
| "Probucol has reduced post-percutaneous coronary intervention (PCI) restenosis and progression of carotid atherosclerosis in clinical trials." | 2.43 | Antioxidants and atherosclerosis: emerging drug therapies. ( Tardif, JC, 2005) |
| "Probucol has also induced regression of carotid atherosclerosis in the Fukuoka Atherosclerosis Trial (FAST)." | 2.42 | Clinical results with AGI-1067: a novel antioxidant vascular protectant. ( Tardif, JC, 2003) |
| "Probucol has been recognized to have antioxidant properties as well as lipid-lowering effects, and contribute to prevention of atherosclerosis." | 2.40 | [Mechanisms of anti-atherogenic action of probucol]. ( Egusa, G; Ohya, T, 1999) |
| "Probucol has the drawback of decreasing high density lipoprotein concentration and is therefore unlikely to influence atheroma in people." | 2.39 | Antioxidants in the prevention of atherosclerosis. ( Olsson, AG; Yuan, XM, 1996) |
| "Probucol also has antioxidant activity, which may inhibit the oxidative modification of LDL that contributes to lipid deposition in blood vessel walls." | 2.38 | Probucol: pharmacology and clinical application. ( Eder, H; Frishman, W; Zimetbaum, P, 1990) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 2.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| "This probucol-induced increase in HO-1 mRNA and inhibition of RASMC proliferation was prevented by the HO inhibitor Sn(IV) protoporphyrin or transfection with small interference RNA (siRNA) to knockdown HO-1, but not by inactive Cu(II) protoporphyrin or scrambled siRNA." | 1.32 | Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. ( Deng, YM; Stocker, R; Witting, PK; Wu, BJ, 2004) |
| "Hematein is a compound isolated from Caesalpinia sappan that has been used in oriental medicine as both an analgesic and an anti-inflammatory agent." | 1.31 | Dietary hematein ameliorates fatty streak lesions in the rabbit by the possible mechanism of reducing VCAM-1 and MCP-1 expression. ( Bok, SH; Choi, JH; Hong, JJ; Hyun, BH; Jeong, TS; Kim, DY; Kim, JR; Lee, CH; Lee, SB; Oh, GT; Oh, SR, 2001) |
| "Probucol treatment also significantly reduced high-density lipoprotein (HDL) levels in apoE-deficient mice, but not in LDLR-deficient mice." | 1.31 | Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice. ( Chen, Z; Ishibashi, S; Shimano, H; Yamada, N; Yoshikawa, T, 2001) |
| "Probucol is a powerful inhibitor of atherosclerosis in a number of animal models." | 1.30 | Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. ( Bird, DA; Fruebis, J; Palinski, W; Steinberg, D; Tangirala, RK; Witztum, JL, 1998) |
| "Quercetin treated animals did not show increased oxidation of LDL (and VLDL in rabbits) and cholesterol levels were not decreased." | 1.30 | Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits. ( Lauridsen, ST; Mortensen, A, 1999) |
| "Probucol treatment resulted in high plasma probucol concentrations, which correlated (r=0." | 1.30 | Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. ( Frohlich, JJ; Godin, DV; McManus, BM; Moghadasian, MH; Rodrigues, B, 1999) |
| "Probucol treatment also accelerated lesion development in apoE+/- mice fed an atherogenic diet, indicating that the adverse effect is not dependent on the complete absence of apoE." | 1.30 | Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. ( Avdievich, E; Jones, RG; Maeda, N; Quarfordt, SH; Reddick, RL; Reynolds, JB; Surles, LK; Zhang, SH, 1997) |
| "Probucol is a potent inhibitor of atherosclerosis in animal models." | 1.30 | Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. ( Fruebis, J; Gonzalez, V; Palinski, W; Silvestre, M, 1997) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| "Probucol was not effective in preventing either cholesterol-induced atherosclerotic lesions or the induction of protein kinase C activity." | 1.30 | Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. ( Azzi, A; Moser, U; Ozer, NK; San, T; Sirikçi, O; Taha, S, 1998) |
| "Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos." | 1.29 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994) |
| "Probucol treatment was associated a threefold increase in LDL resistance to copper-induced oxidative modification (P < 0." | 1.29 | Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation. ( Cunningham, D; Frei, B; Jackson, T; Keaney, JF; Vita, JA; Xu, A, 1995) |
| "Probucol was without effect on this index of in vivo LDL oxidation." | 1.29 | Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. ( Demacker, PN; Kleinveld, HA; Stalenhoef, AF, 1994) |
| "Probucol treatment resulted in a change not only in the size but also the composition of lesions." | 1.28 | Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques. ( Cho, M; Kita, T; Matsuzawa, Y; Nagano, Y; Nakamura, T; Ueda, Y, 1992) |
| "The family members had episodes of cerebral infarction and apparently had atherosclerosis of the internal carotid artery, but no coronary heart disease due to their almost normal level of cholesterol." | 1.28 | A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate. ( Fujita, H; Ihara, Y; Kajinami, K; Kamisaka, K; Kibata, M; Mabuchi, H; Namba, R; Nobukuni, K; Ohshima, K; Shirabe, T, 1991) |
| "1." | 1.28 | The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. ( Daugherty, A; Schonfeld, G; Zweifel, BS, 1991) |
| "Probucol levels were determined, as were the physiological antioxidants alpha and gamma tocopherol (vitamin E)." | 1.28 | Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect? ( Beisiegel, U; Finckh, B; Niendorf, A; Rath, M, 1991) |
| "1." | 1.28 | Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. ( Daugherty, A; Schonfeld, G; Zweifel, BS, 1989) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Probucol treatment (0." | 1.27 | Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit. ( Ishihara, M; Ogawa, H; Tawara, K; Tomikawa, M, 1986) |
| "probucol is a new hypolipaemic agent which differs from similar drugs in current use by its chemical structurae and, probably, by its mode of action." | 1.26 | [The effects of probucol in man (author's transl)]. ( Leutenegger, M, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 32 (20.38) | 18.7374 |
| 1990's | 85 (54.14) | 18.2507 |
| 2000's | 39 (24.84) | 29.6817 |
| 2010's | 1 (0.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, CQ | 3 |
| Somers, PK | 2 |
| Rachita, CL | 1 |
| Holt, LA | 1 |
| Hoong, LK | 2 |
| Zheng, XS | 1 |
| Simpson, JE | 1 |
| Hill, RR | 2 |
| Olliff, LK | 1 |
| Kunsch, C | 2 |
| Sundell, CL | 3 |
| Parthasarathy, S | 3 |
| Saxena, U | 2 |
| Sikorski, JA | 1 |
| Wasserman, MA | 3 |
| Tamura, K | 1 |
| Kato, Y | 2 |
| Ishikawa, A | 1 |
| Himori, M | 1 |
| Yoshida, M | 1 |
| Takashima, Y | 1 |
| Suzuki, T | 1 |
| Kawabe, Y | 2 |
| Cynshi, O | 2 |
| Kodama, T | 3 |
| Niki, E | 3 |
| Shimizu, M | 1 |
| Fukumoto, Y | 2 |
| Horiuchi, K | 1 |
| Takatori, A | 1 |
| Inenaga, T | 1 |
| Ohta, E | 1 |
| Yamanouchi, J | 1 |
| Kawamura, S | 1 |
| Ishii, Y | 1 |
| Kyuwa, S | 1 |
| Yoshikawa, Y | 1 |
| Tardif, JC | 3 |
| Grégoire, J | 1 |
| Schwartz, L | 1 |
| Title, L | 1 |
| Laramée, L | 1 |
| Reeves, F | 1 |
| Lespérance, J | 1 |
| Bourassa, MG | 1 |
| L'Allier, PL | 1 |
| Glass, M | 1 |
| Lambert, J | 1 |
| Guertin, MC | 1 |
| Suen, KL | 1 |
| Landers, LK | 1 |
| Chapman, A | 1 |
| Butteiger, D | 1 |
| Jones, M | 1 |
| Edwards, D | 2 |
| Daugherty, A | 3 |
| Alexander, RW | 1 |
| Medford, RM | 2 |
| Stix, G | 1 |
| Lankin, VZ | 3 |
| Tikhaze, AK | 2 |
| Kukharchuk, VV | 2 |
| Konovalova, GG | 2 |
| Pisarenko, OI | 1 |
| Kaminnyi, AI | 2 |
| Shumaev, KB | 2 |
| Belenkov, YN | 1 |
| Doggrell, SA | 2 |
| Deng, YM | 1 |
| Wu, BJ | 1 |
| Witting, PK | 5 |
| Stocker, R | 6 |
| Kanazawa, M | 1 |
| Wada, Y | 2 |
| Ohno, T | 1 |
| In, H | 1 |
| Yahata, K | 1 |
| Izumi, J | 1 |
| Tanaka, H | 2 |
| Ito, S | 1 |
| Ueno, M | 1 |
| Nakano, M | 1 |
| Gejyo, F | 1 |
| Ohtani, K | 1 |
| Egashira, K | 1 |
| Finné Nielsen, IL | 1 |
| Elbøl Rasmussen, S | 1 |
| Mortensen, A | 2 |
| Ravn-Haren, G | 1 |
| Ma, HP | 1 |
| Knuthsen, P | 1 |
| Hansen, BF | 2 |
| McPhail, D | 1 |
| Freese, R | 1 |
| Breinholt, V | 1 |
| Frandsen, H | 1 |
| Dragsted, LO | 1 |
| Shimokawa, H | 1 |
| Segarra Domènech, J | 1 |
| Santafé Oroz, J | 1 |
| Kritchevsky, D | 3 |
| Singer, D | 1 |
| Klurfeld, DM | 1 |
| Wissler, RW | 1 |
| Vesselinovitch, D | 1 |
| Henahan, J | 1 |
| Glueck, CJ | 1 |
| Marshall, FN | 1 |
| Leutenegger, M | 1 |
| Ogawa, M | 1 |
| Ueda, S | 1 |
| Anzai, N | 1 |
| Ito, K | 1 |
| Ohto, M | 1 |
| Akikusa, B | 1 |
| Chang, MY | 1 |
| Sasahara, M | 2 |
| Chait, A | 2 |
| Raines, EW | 2 |
| Ross, R | 2 |
| Johansson, J | 5 |
| Olsson, AG | 6 |
| Bergstrand, L | 2 |
| Elinder, LS | 3 |
| Nilsson, S | 6 |
| Erikson, U | 5 |
| Mölgaard, J | 4 |
| Holme, I | 2 |
| Walldius, G | 5 |
| Parker, RA | 1 |
| Sabrah, T | 1 |
| Cap, M | 1 |
| Gill, BT | 1 |
| Braesen, JH | 2 |
| Beisiegel, U | 4 |
| Niendorf, A | 2 |
| Keaney, JF | 1 |
| Xu, A | 1 |
| Cunningham, D | 1 |
| Jackson, T | 1 |
| Frei, B | 1 |
| Vita, JA | 1 |
| Morel, DW | 1 |
| de la Llera-Moya, M | 1 |
| Friday, KE | 1 |
| Hådell, K | 2 |
| Kaijser, L | 2 |
| Lassvik, C | 2 |
| Ohtsuka, I | 1 |
| Kogushi, M | 1 |
| Kimura, T | 2 |
| Fujimori, T | 1 |
| Saeki, T | 1 |
| Hayashi, K | 1 |
| Kobayashi, H | 1 |
| Yamada, T | 1 |
| Hiyoshi, H | 1 |
| Kuo, PT | 1 |
| Noguchi, N | 2 |
| Gotoh, N | 1 |
| Kögl, C | 1 |
| Schneider, W | 1 |
| Elstner, EF | 1 |
| Carew, TE | 6 |
| Steinberg, D | 5 |
| Wahl, PW | 1 |
| Fruebis, J | 5 |
| Dresel, HA | 1 |
| Kleinveld, HA | 2 |
| Demacker, PN | 2 |
| Stalenhoef, AF | 2 |
| Pozdniakov, OM | 1 |
| Klimenko, ED | 1 |
| Kobozeva, LP | 1 |
| Michunskaia, AB | 1 |
| Smirnov, LD | 1 |
| Spinler, SA | 1 |
| Cziraky, MJ | 1 |
| Yamaguchi, Y | 1 |
| Kitagawa, S | 1 |
| Imaizumi, N | 1 |
| Kunitomo, M | 1 |
| Fujiwara, M | 1 |
| Nakagawa, S | 1 |
| Ozawa, K | 1 |
| Cleland, JG | 1 |
| Krikler, DM | 1 |
| Regnström, J | 2 |
| Nilsson, J | 3 |
| Schäfer-Elinder, L | 1 |
| Moelgaard, J | 1 |
| Carlson, LA | 2 |
| Schwartz, CJ | 2 |
| Valente, AJ | 1 |
| Sprague, EA | 1 |
| Kuzuya, M | 1 |
| Kuzuya, F | 1 |
| Kosmeijer-Schuil, TG | 1 |
| Katan, MB | 1 |
| Andersen, HO | 1 |
| Holm, P | 1 |
| Nordestgaard, BG | 1 |
| Kjeldsen, K | 1 |
| Stender, S | 1 |
| Tomochika, Y | 2 |
| Okuda, F | 1 |
| Tanaka, N | 1 |
| Wasaki, Y | 1 |
| Tokisawa, I | 1 |
| Aoyagi, S | 2 |
| Morikuni, C | 1 |
| Ono, S | 1 |
| Okada, K | 1 |
| Matsuzaki, M | 2 |
| Pettersson, KS | 1 |
| Ostlund-Lindqvist, AM | 4 |
| Westerlund, C | 4 |
| O'Leary, VJ | 1 |
| Tilling, L | 1 |
| Fleetwood, G | 1 |
| Stone, D | 1 |
| Darley-Usmar, V | 1 |
| Kouzuma, R | 1 |
| Tasaki, H | 1 |
| Komura, T | 1 |
| Nakashima, Y | 1 |
| Kuroiwa, A | 1 |
| Tanimoto, A | 1 |
| Koide, O | 1 |
| Del Rio, M | 1 |
| Chulia, T | 1 |
| Ruiz, E | 1 |
| Tejerina, T | 1 |
| Yuan, XM | 1 |
| Ishigami, M | 1 |
| Yamashita, S | 1 |
| Sakai, N | 1 |
| Hirano, K | 1 |
| Arai, T | 1 |
| Maruyama, T | 1 |
| Takami, S | 1 |
| Koyama, M | 1 |
| Kameda-Takemura, K | 1 |
| Matsuzawa, Y | 2 |
| Zhang, SH | 1 |
| Reddick, RL | 1 |
| Avdievich, E | 1 |
| Surles, LK | 1 |
| Jones, RG | 1 |
| Reynolds, JB | 1 |
| Quarfordt, SH | 1 |
| Maeda, N | 1 |
| Gonzalez, V | 1 |
| Silvestre, M | 2 |
| Palinski, W | 4 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Sevanian, A | 2 |
| Hodis, H | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Dujovne, CA | 2 |
| Jorge, PA | 1 |
| Ozer, NK | 3 |
| Sirikçi, O | 2 |
| Taha, S | 1 |
| San, T | 1 |
| Moser, U | 1 |
| Azzi, A | 2 |
| Baldassarre, D | 1 |
| Franceschini, G | 2 |
| Peruzzotti, G | 1 |
| Brusoni, B | 1 |
| Sirtori, CR | 2 |
| Bird, DA | 2 |
| Pattison, J | 1 |
| Wu, YJ | 1 |
| Hong, CY | 1 |
| Lin, SJ | 2 |
| Wu, P | 1 |
| Shiao, MS | 2 |
| Oshima, R | 1 |
| Ikeda, T | 1 |
| Watanabe, K | 1 |
| Itakura, H | 2 |
| Sugiyama, N | 1 |
| Tangirala, RK | 1 |
| Witztum, JL | 1 |
| Haklar, G | 1 |
| Yalçin, AS | 1 |
| Leng, GC | 1 |
| Price, JF | 1 |
| Jepson, RG | 1 |
| Schwenke, DC | 3 |
| Behr, SR | 2 |
| Benson, GM | 1 |
| Schiffelers, R | 1 |
| Nicols, C | 1 |
| Latcham, J | 1 |
| Vidgeon-Hart, M | 1 |
| Toseland, CD | 1 |
| Suckling, KE | 1 |
| Groot, PH | 1 |
| Donetti, E | 1 |
| Soma, MR | 1 |
| Barberi, L | 1 |
| Paoletti, R | 1 |
| Fumagalli, R | 1 |
| Roma, P | 1 |
| Catapano, AL | 1 |
| Lauridsen, ST | 1 |
| Pettersson, K | 4 |
| Eriksson, AW | 1 |
| Moghadasian, MH | 1 |
| McManus, BM | 1 |
| Godin, DV | 1 |
| Rodrigues, B | 1 |
| Frohlich, JJ | 1 |
| Witting, P | 1 |
| Wâgberg, M | 2 |
| Byun, J | 1 |
| Mueller, DM | 1 |
| Fabjan, JS | 1 |
| Heinecke, JW | 1 |
| Allott, CP | 1 |
| Barry, CD | 1 |
| Bramley, J | 1 |
| John, NW | 1 |
| Mellor, PM | 1 |
| Thomson, DS | 1 |
| Reilly, CF | 1 |
| Shelton, D | 1 |
| Napoli, C | 1 |
| Ohya, T | 1 |
| Egusa, G | 1 |
| El-Swefy, S | 1 |
| Schaefer, EJ | 1 |
| Seman, LJ | 1 |
| van Dongen, D | 1 |
| Smith, DE | 1 |
| Ordovas, JM | 1 |
| El-Sweidy, M | 1 |
| Meydani, M | 1 |
| Lau, AK | 1 |
| Chaufour, X | 1 |
| Celermajer, DS | 1 |
| Niemann-Jönsson, A | 1 |
| Dimayuga, P | 1 |
| Jovinge, S | 1 |
| Calara, F | 1 |
| Ares, MP | 1 |
| Fredrikson, GN | 1 |
| Titov, VN | 1 |
| Zaĭtseva, TM | 2 |
| Pfuetze, KD | 1 |
| Djahansouzi, S | 1 |
| Koenig, K | 2 |
| Kontush, A | 2 |
| Kozachenko, AI | 1 |
| Gurevich, SM | 1 |
| Nagler, LG | 1 |
| Chin-Dusting, JP | 1 |
| Shaw, JA | 1 |
| Yagyu, H | 1 |
| Mashima, R | 1 |
| Takabe, W | 1 |
| Mataki, C | 1 |
| Ishii, M | 1 |
| Izumi, A | 1 |
| Aburatani, H | 1 |
| Hamakubo, T | 2 |
| Yoshikawa, T | 2 |
| Shimano, H | 1 |
| Chen, Z | 1 |
| Ishibashi, S | 1 |
| Yamada, N | 1 |
| Jansson, AH | 1 |
| Särnstrand, B | 1 |
| Bergstrand, H | 1 |
| Oh, GT | 1 |
| Choi, JH | 1 |
| Hong, JJ | 1 |
| Kim, DY | 1 |
| Lee, SB | 1 |
| Kim, JR | 1 |
| Lee, CH | 1 |
| Hyun, BH | 1 |
| Oh, SR | 1 |
| Bok, SH | 1 |
| Jeong, TS | 1 |
| Inoue, K | 1 |
| Nakamura, M | 1 |
| Miyauchi, K | 1 |
| Daida, H | 1 |
| Yamaguchi, H | 1 |
| Russell, JC | 1 |
| Yoshida, N | 1 |
| Murase, H | 1 |
| Kunieda, T | 1 |
| Toyokuni, S | 1 |
| Tanaka, T | 1 |
| Terao, J | 1 |
| Naito, Y | 1 |
| Tanigawa, T | 1 |
| Yang, TH | 1 |
| Chen, YH | 1 |
| Chen, JW | 1 |
| Kwok, CF | 1 |
| Chen, YL | 1 |
| Itoh, S | 1 |
| Umemoto, S | 1 |
| Hiromoto, M | 1 |
| Toma, Y | 1 |
| Tanaka, M | 1 |
| Fujii, T | 1 |
| Bräsen, JH | 1 |
| Bach, H | 1 |
| Heinle, H | 1 |
| Ylä-Herttuala, S | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Kisanuki, A | 1 |
| Asada, Y | 1 |
| Hatakeyama, K | 1 |
| Hayashi, T | 1 |
| Sumiyoshi, A | 1 |
| Bocan, TM | 1 |
| Mueller, SB | 1 |
| Brown, EQ | 1 |
| Uhlendorf, PD | 1 |
| Mazur, MJ | 1 |
| Newton, RS | 1 |
| Naruszewicz, M | 1 |
| Selinger, E | 1 |
| Dufour, R | 1 |
| Davignon, J | 2 |
| Jialal, I | 1 |
| Grundy, SM | 1 |
| Babiy, AV | 1 |
| Gebicki, JM | 1 |
| Sullivan, DR | 1 |
| Willey, K | 1 |
| Nagano, Y | 7 |
| Nakamura, T | 1 |
| Cho, M | 1 |
| Ueda, Y | 2 |
| Kita, T | 9 |
| Ihara, Y | 1 |
| Nobukuni, K | 1 |
| Namba, R | 1 |
| Kamisaka, K | 1 |
| Kibata, M | 1 |
| Kajinami, K | 1 |
| Fujita, H | 1 |
| Mabuchi, H | 1 |
| Shirabe, T | 1 |
| Ohshima, K | 1 |
| Mimura, K | 1 |
| Yukawa, S | 1 |
| Avogaro, P | 1 |
| Cazzolato, G | 1 |
| Bittolo-Bon, G | 1 |
| Jackson, RL | 2 |
| Barnhart, RL | 1 |
| Mao, SJ | 1 |
| Zweifel, BS | 2 |
| Schonfeld, G | 2 |
| Lupanov, VP | 1 |
| Liakishev, AA | 1 |
| Revenko, VM | 1 |
| Chiesa, G | 1 |
| Hsiang, Y | 1 |
| White, RA | 1 |
| Kopchok, GE | 1 |
| Rosenbaum, D | 1 |
| Guthrie, C | 1 |
| Kao, J | 1 |
| Zhen, EZ | 1 |
| Peng, SK | 1 |
| Fragoso, M | 1 |
| Chisolm, GM | 1 |
| Finckh, B | 1 |
| Rath, M | 1 |
| Weis, JR | 1 |
| Pitas, RE | 1 |
| Wilson, BD | 1 |
| Rodgers, GM | 1 |
| Carpenter, KL | 1 |
| Ballantine, JA | 1 |
| Fussell, B | 1 |
| Enright, JH | 1 |
| Mitchinson, MJ | 1 |
| Ishii, K | 6 |
| Yokode, M | 4 |
| Kume, N | 4 |
| Otani, H | 1 |
| Arai, H | 2 |
| Kawai, C | 4 |
| Zimetbaum, P | 1 |
| Eder, H | 1 |
| Frishman, W | 1 |
| Stein, Y | 1 |
| Stein, O | 1 |
| Delplanque, B | 1 |
| Fesmire, JD | 1 |
| Lee, DM | 1 |
| Alaupovic, P | 1 |
| Mori, Y | 1 |
| Wada, H | 1 |
| Deguchi, K | 1 |
| Shirakawa, S | 1 |
| Bellamy, MF | 1 |
| Nealis, AS | 1 |
| Aitken, JW | 1 |
| Bruckdorfer, KR | 1 |
| Perkins, SJ | 1 |
| Shankar, R | 1 |
| Sallis, JD | 1 |
| Stanton, H | 1 |
| Thomson, R | 1 |
| Franzone, JS | 1 |
| Cravanzola, C | 1 |
| Reboani, MC | 1 |
| Torrielli, MV | 1 |
| Pernigotti, ML | 1 |
| Ku, G | 1 |
| Doherty, NS | 1 |
| Wolos, JA | 1 |
| Stenport, G | 2 |
| Tikkanen, MJ | 1 |
| Helve, E | 1 |
| Nikkilä, EA | 1 |
| Cohen, L | 1 |
| Morgan, J | 1 |
| Narumiya, S | 1 |
| Yamamoto, A | 1 |
| Hara, H | 1 |
| Takaichi, S | 1 |
| Wakasugi, J | 1 |
| Tomikawa, M | 2 |
| Ooshima, A | 1 |
| Yoshida, H | 1 |
| Tawara, K | 1 |
| Ishihara, M | 1 |
| Ogawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| EFFECT OF PLANT STEROLS ON THE LIPID PROFILE OF PATIENTS WITH HYPERCHOLESTEROLAEMIA. RANDOMISED, EXPERIMENTAL STUDY[NCT01406106] | 182 participants (Actual) | Interventional | 2010-01-31 | Active, not recruiting | |||
| A Study in Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis[NCT03821090] | 160 participants (Actual) | Observational | 2019-04-15 | Completed | |||
| Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome[NCT00988364] | Phase 4 | 30 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy[NCT02644239] | 60 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient's blood samples were collected at the corresponding time point for L5 purification. L5 quantification and characterization were investigated with chemical analysis, proteomics and in-vitro cell signaling analysis. Final data analysis will determine total L5 concentration (mg/dL). (NCT00988364)
Timeframe: 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Ezetimibe | 30.17 |
| Simvastatin | 19.19 |
| Vytorin | 14.17 |
| Placebo | 15.15 |
Patient's blood samples were collected before treatment. L5 were purified by ultracentrifugation then FPLC. Quantification analysis will indicate the L5 concentration (mg/dL) per group. (NCT00988364)
Timeframe: 0 months, at the start
| Intervention | mg/dL (Mean) |
|---|---|
| Ezetimibe | 35.97 |
| Simvastatin | 17.8233 |
| Vytorin | 29.736 |
| Placebo | 23.1 |
37 reviews available for probucol and Arteriosclerosis
| Article | Year |
|---|---|
Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Topics: Antioxidants; Arteriosclerosis; Cardiovascular System; Coronary Artery Disease; Humans; Probucol; Si | 2003 |
Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Humans; Oxidative Stress; Probucol | 2003 |
Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronar | 2003 |
[NO and atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Arginine; Arteriosclerosis; Endothe | 2004 |
Antioxidants and atherosclerosis: emerging drug therapies.
Topics: Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Coronary Restenosis; Humans; Oxidative Str | 2005 |
[Adverse effects of lipid-lowering medications].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibric Acid; Contraindications; Humans; Hydroxymethyl | 2007 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Ge | 1983 |
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1982 |
Pharmacology and toxicology of probucol.
Topics: Animals; Arteriosclerosis; Cholesterol; Dogs; Feces; Heart Diseases; Macaca fascicularis; Macaca mul | 1982 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
Lipoprotein(A): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Humans; Hydroxymethyl | 1994 |
Modification of atherosclerosis by agents that do not lower cholesterol.
Topics: Animals; Antioxidants; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Fibrinolytic Agents; Hep | 1993 |
A modern view of atherogenesis.
Topics: Animals; Antioxidants; Arteriosclerosis; Humans; Lipoproteins, LDL; Monocytes; Oxidation-Reduction; | 1993 |
Probucol as an antioxidant and antiatherogenic drug.
Topics: Animals; Antioxidants; Arteriosclerosis; Cell Membrane; Cholesterol; Free Radicals; Humans; Lipoprot | 1993 |
The potential of antioxidants to prevent atherosclerosis development and its clinical manifestations.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Antioxidants; Arteries; Arteriosc | 1996 |
Antioxidants in the prevention of atherosclerosis.
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; beta Carotene; Humans; Iron Chelating Agen | 1996 |
Antioxidants and atherosclerosis: an overview.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease Models, Animal; Humans; P | 1997 |
New lipid lowering drugs and new effects of old drugs.
Topics: Anticholesteremic Agents; Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; | 1997 |
[Endothelium, lipids and atherosclerosis].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Endocytosis; Endothelium, Vascular; Foam Cells; | 1997 |
[Mechanisms of anti-atherogenic action of probucol].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Humans; Lipoproteins, HDL; Probucol | 1999 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA | 2001 |
[Probucol].
Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; C | 2001 |
[Antioxidants].
Topics: Animals; Antioxidants; Arteriosclerosis; Ascorbic Acid; Carotenoids; Clinical Trials as Topic; Coron | 2001 |
Oxidants and antioxidants in atherosclerosis.
Topics: Antioxidants; Arteriosclerosis; Free Radicals; Humans; Lipid Peroxidation; Lipoproteins, LDL; Nitric | 2001 |
Type 2 diabetes: pharmacological intervention in an animal model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Calcium Channel Blockers; Diabe | 2001 |
Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
Topics: Animals; Arteriosclerosis; Clofibrate; Dogs; Humans; Hypercholesterolemia; Hyperlipidemias; Kinetics | 1978 |
Newer hypolipidemic compounds.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Clofibrate; Halofenate; Humans; Hypoli | 1975 |
Influence of antioxidant vitamins on LDL oxidation.
Topics: Animals; Arteriosclerosis; Ascorbic Acid; Humans; Lipoproteins, LDL; Oxidation-Reduction; Probucol; | 1992 |
Probucol and its mechanisms for reducing atherosclerosis.
Topics: Antioxidants; Arteriosclerosis; Humans; Probucol | 1991 |
[Mechanisms of anti-atherogenic effect of probucol and the prospects of its clinical use].
Topics: Arteriosclerosis; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Drug Evaluation; Humans; Hyperch | 1991 |
Antioxidants and atherosclerosis: a current assessment.
Topics: Animals; Antioxidants; Arteriosclerosis; Cholesterol, Dietary; Free Radical Scavengers; Humans; Lipo | 1991 |
Probucol: pharmacology and clinical application.
Topics: Animals; Arteriosclerosis; Humans; Phenols; Probucol | 1990 |
Role of biologically modified low-density lipoprotein in atherosclerosis.
Topics: Animals; Arteriosclerosis; Cholesterol; Humans; Lipoproteins, LDL; Lovastatin; Oxidation-Reduction; | 1989 |
The probucol experience: a review of the past and a look at the future.
Topics: Animals; Antioxidants; Arteriosclerosis; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Hype | 1988 |
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Topics: Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hype | 1987 |
11 trials available for probucol and Arteriosclerosis
| Article | Year |
|---|---|
Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Coronary D | 2003 |
Decrease of urine protein after treatment with probucol in patients with mild glomerulonephritis and arteriolosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Glomerulonephritis; Humans; Male; M | 1995 |
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Topics: Apolipoprotein A-I; Arteriosclerosis; Cholesterol, HDL; Cholestyramine Resin; Female; Femoral Artery | 1995 |
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Fem | 1994 |
The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
Topics: Aged; Antioxidants; Arteriosclerosis; Cholesterol; Dietary Fats; Double-Blind Method; Female; Humans | 1993 |
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Topics: Adult; Angiography; Anticholesteremic Agents; Arteriosclerosis; Disease Progression; Female; Femoral | 1996 |
[Antioxidant probucol is an efficient trap for lipid radicals in LDL in vitro and in vivo].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Electron Spin Resonance Spectroscopy; Free | 1999 |
Stenosis following laser thermal angioplasty--a blinded controlled randomized study between aspirin against Probucol.
Topics: Angioplasty, Laser; Animals; Aorta; Arteriosclerosis; Aspirin; Constriction, Pathologic; Female; Hot | 1991 |
Changes in atheroma volume estimated from digitized femoral arteriograms.
Topics: Algorithms; Angiography, Digital Subtraction; Arteriosclerosis; Double-Blind Method; Female; Femoral | 1990 |
Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery.
Topics: Arteriosclerosis; Clinical Trials as Topic; Femoral Artery; Humans; Methods; Phenols; Probucol; Radi | 1988 |
Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Combined Modality Therapy; Drug Th | 1988 |
109 other studies available for probucol and Arteriosclerosis
| Article | Year |
|---|---|
Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis.
Topics: Animals; Antioxidants; Arteriosclerosis; Humans; Phenols; Tumor Necrosis Factor-alpha; Vascular Cell | 2002 |
Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants.
Topics: alpha-Tocopherol; Animals; Antioxidants; Arteriosclerosis; Benzofurans; Free Radicals; Linoleic Acid | 2003 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F | 2012 |
The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Cricetinae; D | 2002 |
AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Disease | 2003 |
Signal jammer. An academic experiment leads to a new class of drug for attacking heart disease.
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; H | 2003 |
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Topics: Animals; Antioxidants; Arteriosclerosis; Coenzymes; Dose-Response Relationship, Drug; Double-Blind M | 2003 |
Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta, Abdominal; Apoptosis; Arteriosclerosis; Cath | 2004 |
Mixed connective tissue disease associated with antineutrophil cytoplasmic antibodies against proteinase-3 and systemic atherosclerosis: a case report.
Topics: Antibodies, Antineutrophil Cytoplasmic; Arteriosclerosis; Aspirin; Autoantibodies; Cholesterol, LDL; | 2004 |
Anthocyanins increase low-density lipoprotein and plasma cholesterol and do not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits.
Topics: Animals; Anthocyanins; Aorta; Arteriosclerosis; Beverages; Cholesterol; Cholesterol, VLDL; Diet; Ery | 2005 |
Influence of hypocholesterolemic drugs on aortic cholesterol esterase in rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Carboxylic Ester Hydrolases; Cholesterol | 1984 |
Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholestyramine Resin; Diet, Atherogenic; Drug The | 1983 |
Regression of atherosclerosis: preliminary but encouraging news.
Topics: Adult; Animals; Arteriosclerosis; Child; Haplorhini; Humans; Intestine, Small; Male; Middle Aged; Ph | 1981 |
Probucol-lipid pharmacology.
Topics: Animals; Arteriosclerosis; Cholesterol; Clofibrate; Feces; Haplorhini; Humans; Lipid Metabolism; Lip | 1982 |
[The effects of probucol in man (author's transl)].
Topics: Anticholesteremic Agents; Arteriosclerosis; Bile; Clofibrate; Electrocardiography; Heart; Humans; Hy | 1980 |
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins B; Arteries; Arteriosclerosis; Cell Divisi | 1995 |
Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Corn Oil; Cricetinae; Diet, Atherogenic; Dose-Respon | 1995 |
Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits.
Topics: Animals; Arteriosclerosis; Female; Hyperlipoproteinemia Type II; Male; Probucol; Rabbits | 1995 |
Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
Topics: Animals; Antioxidants; Arteries; Arteriosclerosis; Body Weight; Cholesterol; Diet, Atherogenic; Endo | 1995 |
Treatment of cholesterol-fed rabbits with dietary vitamins E and C inhibits lipoprotein oxidation but not development of atherosclerosis.
Topics: Animals; Arteriosclerosis; Ascorbic Acid; Cholesterol, Dietary; Drug Interactions; Lipoproteins; Oxi | 1994 |
Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits.
Topics: Anilides; Animals; Aorta, Thoracic; Arteriosclerosis; Cholestyramine Resin; Dose-Response Relationsh | 1994 |
Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals.
Topics: Amidines; Antioxidants; Apolipoproteins B; Arteriosclerosis; Azoles; Copper; Free Radicals; Humans; | 1994 |
The influence of magnesium-pyridoxal-5'-phosphate-glutamate in comparison with probucol, alpha-tocopherol and trolox on copper-induced oxidation of human low density lipoprotein in vitro.
Topics: Arteriosclerosis; Chromans; Copper; Fatty Acids; Glutamine; Humans; In Vitro Techniques; Lipoprotein | 1994 |
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Hypercholesterolemia; Lipoproteins | 1994 |
A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Female; Lipoproteins, LDL; Male; Oxidation-Reduction | 1994 |
Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Dose-Response Relationship, Drug; Hyperlipidemias; Lipid Peroxides | 1994 |
[Synthetic antioxidant correction for disorders of the regulatory and microcirculatory systems in the early stages of experimental atherosclerosis].
Topics: Adrenal Glands; Animals; Antioxidants; Arteriosclerosis; Diet, Atherogenic; Hypothalamo-Hypophyseal | 1993 |
Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Desmo | 1993 |
Protective aspects for atherogenesis and lipid abnormalities in continuous ambulatory peritoneal dialysis patients.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Creatinine; Female; Glutathione Peroxidase; Humans; Hyper | 1993 |
In vivo oxidised cholesterol in atherosclerosis.
Topics: Animals; Arteriosclerosis; Cholesterol; Lipoproteins, LDL; Oxidation-Reduction; Probucol; Rabbits | 1993 |
Effect of the antioxidant probucol on transplant arteriosclerosis in aorta-allografted rabbits.
Topics: Animals; Antioxidants; Aorta, Abdominal; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Cholesterol | 1995 |
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiograph | 1996 |
The resistance of low density lipoprotein to oxidation promoted by copper and its use as an index of antioxidant therapy.
Topics: Administration, Oral; Animals; Antioxidants; Aortic Diseases; Arteriosclerosis; Blood; Copper; Disea | 1996 |
Combined treatment of probucol with diltiazem regresses atherosclerosis induced by 196 cholesterol diet in rabbit aorta.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cardiovascular Agents; Cholesterol; Chol | 1995 |
Action of probucol in arteries from normal and hypercholesterolaemic rabbits.
Topics: Animals; Anticholesteremic Agents; Arteries; Arteriosclerosis; Calcium; Calcium Radioisotopes; Chole | 1996 |
High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins.
Topics: Adult; Animals; Anticholesteremic Agents; Arteriosclerosis; Carrier Proteins; Cholesterol; Cholester | 1997 |
Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein A-I; Apolipoproteins E; Arteriosclerosis; C | 1997 |
Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis.
Topics: Animals; Arteriosclerosis; Chemokine CCL2; Gene Expression; Immunohistochemistry; Macrophage Colony- | 1997 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Endot | 1998 |
Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Ca | 1997 |
Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants.
Topics: Animals; Antioxidants; Arteriosclerosis; Body Weight; Cholesterol; Lipid Peroxidation; Lipoproteins, | 1997 |
Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Bepridil; Biphenyl Compoun | 1998 |
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Actins; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arter | 1998 |
Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol, Dietary; Female; Lipoproteins, HDL | 1998 |
Measurement of reactive oxygen species by chemiluminescence in diet-induced atherosclerosis: protective roles of vitamin E and probucol on different radical species.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Luminescent Measurements; Male; | 1998 |
Lipid lowering therapy in the treatment of lower limb atherosclerosis.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Data Collection; Databases, Bi | 1998 |
Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations.
Topics: Animals; Aorta; Arteriosclerosis; Ascorbic Acid; Cholesterol; Diet, Atherogenic; Drug Therapy, Combi | 1998 |
Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Dietary Fats; Female; Lipid | 1998 |
Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidant | 1998 |
Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Hyperlipidem | 1999 |
Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice.
Topics: Animals; Antioxidants; Aorta; Apolipoproteins E; Arteriosclerosis; Benzhydryl Compounds; Cholesterol | 1999 |
Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Apolipoproteins E; Arteriosclerosi | 1999 |
Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Hyperlipidemias; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Ma | 1999 |
Nitrogen dioxide radical generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid peroxidation of low density lipoprotein.
Topics: Antioxidants; Arteriosclerosis; Ascorbic Acid; Free Radicals; HL-60 Cells; Humans; Hydrogen Peroxide | 1999 |
Noninvasive 3-D ultrasound of atherosclerotic plaques in the Watanabe rabbit.
Topics: Algorithms; Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; F | 1999 |
Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Copper; | 1999 |
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured | 2000 |
Protective effects of probucol in two animal models of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Apolipoproteins E; Arterioscle | 2000 |
Effect of vitamin E on the development of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cell Division; Cell Line; Cholesterol; Choleste | 2000 |
Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression.
Topics: Animals; Antioxidants; Aorta; Apolipoproteins B; Arteriosclerosis; Cells, Cultured; Endothelium, Vas | 2000 |
The effect of pharmacological doses of different antioxidants on oxidation parameters and atherogenesis in hyperlipidaemic rabbits.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Antidotes; Antioxidants; Aorta; Arterioscle | 2001 |
Gene expression induced by BO-653, probucol and BHQ in human endothelial cells.
Topics: Antioxidants; Arteriosclerosis; Benzofurans; Cells, Cultured; Cysteine Endopeptidases; Cytochrome P- | 2000 |
Effects of probucol on atherosclerosis of apoE-deficient or LDL receptor-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cholesterol, HD | 2001 |
Alpha-tocopherol and probucol reduce autoantibody titer to MDA-LDL in hypercholesterolemic rabbits.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Autoanti | 2001 |
N,N'-diacetyl-L-cystine (DiNAC), the disulphide dimer of N-acetylcysteine, inhibits atherosclerosis in WHHL rabbits: evidence for immunomodulatory agents as a new approach to prevent atherosclerosis.
Topics: Acetylcysteine; Adjuvants, Immunologic; Animals; Antioxidants; Arteriosclerosis; Cholesterol; Cystin | 2001 |
Dietary hematein ameliorates fatty streak lesions in the rabbit by the possible mechanism of reducing VCAM-1 and MCP-1 expression.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Blotting, Northern; Caesalpini | 2001 |
Effect of BO-653 and probucol on c-MYC and PDGF-A messenger RNA of the iliac artery after balloon denudation in cholesterol-fed rabbits.
Topics: Analysis of Variance; Animals; Antioxidants; Arteriosclerosis; Base Sequence; Benzofurans; Catheteri | 2002 |
Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Arteriosclerosis; Aspartate Aminotransferases; B | 2002 |
Effects of Ginkgo biloba extract on the proliferation of vascular smooth muscle cells in vitro and on intimal thickening and interleukin-1beta expression after balloon injury in cholesterol-fed rabbits in vivo.
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Arterios | 2002 |
Immunomodulation with DiNAC-- a new approach to the treatment of atherosclerosis?
Topics: Adjuvants, Immunologic; Animals; Arteriosclerosis; Benzhydryl Compounds; Cystine; Dermatitis, Contac | 2002 |
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Choleste | 2002 |
Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits.
Topics: alpha-Tocopherol; Animals; Antioxidants; Aorta; Arteriosclerosis; Coenzymes; Disease Models, Animal; | 2002 |
Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Hypercholesterolemia; Immunohistoc | 1992 |
Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Ascorbic Acid; Blood Vessels; Cholesterol; Cholester | 1992 |
Probucol protects lipoprotein (a) against oxidative modification.
Topics: Adult; Arteriosclerosis; Cholesterol; Cholesterol, LDL; Female; Humans; Lipoprotein(a); Macrophages; | 1992 |
[Clinical study of lipid metabolism disorders (discussion)].
Topics: Arteriosclerosis; Cholestyramine Resin; Diet; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; | 1992 |
Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation.
Topics: Adult; Arteriosclerosis; Diabetes Complications; Diabetes Mellitus; Female; Glycosylation; Humans; L | 1992 |
Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Female; Hyperlipidemias; Lipids; Male; Probucol; Rabb | 1992 |
A family of familial hypercholesterolemia with cerebral infarction and without coronary heart disease. An unusual case with corneal opacity, polyneuropathy and carpal tunnel syndrome in the family: therapy with probucol and tocopherol nicotinate.
Topics: Arteriosclerosis; Axons; Carpal Tunnel Syndrome; CD4-CD8 Ratio; Cerebral Infarction; Corneal Opacity | 1991 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.
Topics: Animals; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipids; Lipoproteins, LDL; Oxidation-Reduct | 1991 |
Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients.
Topics: Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholest | 1991 |
Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?
Topics: Animals; Antioxidants; Arteriosclerosis; Female; Hyperlipidemias; Lipid Peroxidation; Male; Probucol | 1991 |
Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation.
Topics: Anticoagulants; Arteriosclerosis; Ascorbic Acid; Cells, Cultured; Dextran Sulfate; Dose-Response Rel | 1991 |
Oxidation of cholesteryl linoleate by human monocyte-macrophages in vitro.
Topics: Arteriosclerosis; Butylated Hydroxytoluene; Cells, Cultured; Cholesterol Esters; Edetic Acid; Free R | 1990 |
Lipoproteins and atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholestyramine | 1990 |
The role of oxidized low density lipoprotein in the pathogenesis of atherosclerosis.
Topics: Animals; Arteriosclerosis; Cells, Cultured; Hyperlipidemia, Familial Combined; Lipoproteins, LDL; Li | 1990 |
[Modified LDL and its physiological significance].
Topics: Animals; Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol; Re | 1990 |
[Prevention of atherosclerosis using an antioxidant].
Topics: Animals; Antioxidants; Aortic Diseases; Arteriosclerosis; Cholesterol, LDL; Macrophages; Oxidation-R | 1990 |
[Recent trend in the research of hyperlipidemia in Japan. Influence of defective metabolism of low-density lipoprotein on atherosclerosis].
Topics: Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol | 1989 |
Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels.
Topics: Animals; Aorta; Apolipoproteins; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Male; Phenols; | 1989 |
Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation.
Topics: Aging; Animals; Arteriosclerosis; Blood Coagulation Factors; Disease Models, Animal; Hyperlipidemias | 1989 |
Structural changes in oxidised low-density lipoproteins and of the effect of the anti-atherosclerotic drug probucol observed by synchrotron X-ray and neutron solution scattering.
Topics: Apolipoprotein B-100; Apolipoproteins B; Arteriosclerosis; Copper; Humans; Lipoproteins, LDL; Macrom | 1989 |
Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats.
Topics: Animals; Arteriosclerosis; Cell Adhesion; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; | 1989 |
Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Aorta; Aortic Diseases; Arteriosclerosis; Cholesterol Esters; Cholesterol, Dietary; Diet; L | 1989 |
Biological properties of pancreatic elastase in relation to atherosclerotic disease.
Topics: Animals; Antacids; Arteriosclerosis; Calcium; Citrates; Citric Acid; Clofibrate; Diet, Atherogenic; | 1988 |
Inhibition by probucol of interleukin 1 secretion and its implication in atherosclerosis.
Topics: Animals; Arteriosclerosis; In Vitro Techniques; Interleukin-1; Lipopolysaccharides; Lipoproteins, LD | 1988 |
Biological modification of lipoproteins and its role in atherogenesis.
Topics: Animals; Arteriosclerosis; Chemical Phenomena; Chemistry; Hyperlipidemia, Familial Combined; Lipopro | 1988 |
Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Fe | 1988 |
Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
Topics: Animals; Arteriosclerosis; Cells, Cultured; Drug Evaluation, Preclinical; Female; Foam Cells; Hyperl | 1988 |
Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.
Topics: Arteriosclerosis; Cell Line; Cholesterol; Depression, Chemical; Foam Cells; Humans; Lipid Metabolism | 1988 |
In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
Topics: Animals; Arteriosclerosis; Depression, Chemical; Drug Evaluation, Preclinical; Foam Cells; Hyperlipi | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol; Disease Models, Animal; Female; Hyperlipopr | 1987 |
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipoproteins, LDL; Lov | 1987 |
Effect of probucol, pantethine and their combinations on serum lipoprotein metabolism and on the incidence of atheromatous lesions in the rabbit.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Drug Synergism; Lipoproteins; Male; Pa | 1986 |